The Medical Devices Rules, 2017, represent a paradigm shift in India's approach to medical device regulation. Critically analyse the regulatory framework with reference to risk-based classification and its implications for patient safety and ease of doing business.

Q. The Medical Devices Rules, 2017, represent a paradigm shift in India's approach to medical device regulation. Critically analyse the regulatory framework with reference to risk-based classification and its implications for patient safety and ease of doing business. (15 marks, 250-350 words)

Notified under the Drugs and Cosmetics Act, 1940 and effective from 1 January 2018, the Medical Devices Rules (MDR), 2017 replaced the fragmented practice of regulating devices as "drugs" with a dedicated, risk-proportionate and globally harmonised regime [1]. The shift is genuine in design, though uneven in execution.

The paradigm shift: risk-based classification - Devices are graded into four risk classes — A (low, e.g. surgical gloves), B, C and D (high, e.g. heart valves) — on the GHTF/IMDRF template, enabling regulatory convergence for exporters [1]. - Regulatory federalism: State Licensing Authorities handle Class A and B; the Central Licensing Authority (CDSCO) handles Class C and D — apt for health, a Concurrent List subject [1]. - Licences are perpetual, valid until suspended or surrendered, ending rent-seeking around periodic renewals [1].

Gains for ease of doing business - A single online portal, defined regulator-side timelines and self-certification for Class A compress time-to-market and reduce discretionary interface [1]. - The draft amendment of 28 June 2026 rationalises licensing timelines — for Class C/D devices such as cardiac stents and orthopaedic implants, from 105 to 90 days — with stage-wise limits for scrutiny, notified-body audit and issuance [2]. - This complements the National Medical Devices Policy, 2023 (approved 26 April 2023), which seeks an enabling manufacturing ecosystem to cut import dependence [3].

Persisting concerns for patient safety - Lighter front-end scrutiny shifts the burden to post-market surveillance, where adverse-event reporting and materiovigilance remain thin. - CDSCO capacity constraints and reliance on accredited Notified Bodies raise questions of audit quality and conflict of interest. - Coverage widened only gradually — eight further categories were brought under regulation in 2021 — leaving legacy devices historically untested [4].

MDR 2017 thus marks a shift from prohibition-centric to risk-calibrated regulation, and faster timelines are welcome. Sustaining it requires investment in regulatory capacity, robust materiovigilance and harmonised Centre–State practice, so that speed and patient safety advance together rather than at each other's cost.

(~330 words)

Sources: 1. Health Ministry Notifies Medical Devices Rules, 2017 (PIB) — risk classes A–D, GHTF basis, CLA/SLA split, perpetual licences, online portal, Class A self-certification 2. Union Ministry of Health and Family Welfare Proposes Amendments to Medical Devices Rules, 2017 to Streamline Licensing Process (PIB) — 2026 draft notification; 105-to-90-day timeline and stage-wise limits 3. Cabinet approves the Policy for the Medical Devices Sector (PIB) — National Medical Devices Policy, 2023 and its manufacturing-ecosystem objective 4. New Regulatory Regime for 8 Medical Items under Drugs and Cosmetics Act (PIB) — phased expansion of regulated device categories